Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
MNKD 
MannKind Corp (MNKD)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/16/2025: MNKD (3-star) is a STRONG-BUY. BUY since 14 days. Simulated Profits (18.81%). Updated daily EoD!
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Number of Analysts
7 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $10.57
1 Year Target Price $10.57
| 6 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 50.4% | Avg. Invested days 33 | Today’s Advisory Strong Buy |
Upturn Star Rating | Upturn Advisory Performance  5.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 09/16/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.71B USD | Price to earnings Ratio 48.91 | 1Y Target Price 10.57 |
Price to earnings Ratio 48.91 | 1Y Target Price 10.57 | ||
Volume (30-day avg) 7 | Beta 1.02 | 52 Weeks Range 3.38 - 7.63 | Updated Date 09/15/2025 |
52 Weeks Range 3.38 - 7.63 | Updated Date 09/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.11 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 10.87% | Operating Margin (TTM) 13.93% |
Management Effectiveness
Return on Assets (TTM) 10.63% | Return on Equity (TTM) - |
Valuation
Trailing PE 48.91 | Forward PE 34.84 | Enterprise Value 1576870825 | Price to Sales(TTM) 5.66 |
Enterprise Value 1576870825 | Price to Sales(TTM) 5.66 | ||
Enterprise Value to Revenue 5.23 | Enterprise Value to EBITDA 19.93 | Shares Outstanding 306828000 | Shares Floating 300980187 |
Shares Outstanding 306828000 | Shares Floating 300980187 | ||
Percent Insiders 1.66 | Percent Institutions 55.86 |
Upturn AI SWOT
MannKind Corp
Company Overview
History and Background
MannKind Corp was founded in 1991. Its early focus was on inhaled insulin technology. A significant milestone was the FDA approval of Afrezza in 2014 (originally 2006 but later withdrawn and resubmitted). The company has evolved to focus on inhaled therapeutics.
Core Business Areas
- Inhaled Therapeutics: MannKind focuses on developing and commercializing inhaled therapeutic products, primarily using its Technosphere platform.
- Afrezza (Inhaled Insulin): Afrezza is MannKind's main product, an inhaled rapid-acting insulin for managing blood sugar levels in adults with diabetes mellitus.
- Tyvaso DPI (Inhaled Treprostinil): Collaboration with United Therapeutics for Tyvaso DPI, an inhaled prostacyclin analogue for pulmonary hypertension.
Leadership and Structure
Michael Castagna is the CEO. The company has a typical corporate structure with a board of directors and executive management team overseeing various departments like R&D, commercial operations, and finance.
Top Products and Market Share
Key Offerings
- Afrezza: Afrezza is an inhaled rapid-acting insulin used to control high blood sugar in adults with diabetes. Market share is small relative to injected insulin. Competitors include Novo Nordisk (NovoLog, Fiasp), Eli Lilly (Humalog, Lyumjev), and Sanofi (Apidra).
- Tyvaso DPI: Tyvaso DPI, partnered with United Therapeutics, is an inhaled prostacyclin analogue for pulmonary hypertension. Competitors include liquid Tyvaso from United Therapeutics itself and other therapies for pulmonary hypertension.
Market Dynamics
Industry Overview
The pharmaceutical industry is highly competitive and regulated. The diabetes and pulmonary hypertension segments are substantial markets with ongoing innovation and demand for new therapies.
Positioning
MannKind is positioned as a specialty pharmaceutical company focused on inhaled therapies. Its competitive advantage lies in its Technosphere platform, which allows for rapid absorption and precise dosing of inhaled drugs.
Total Addressable Market (TAM)
The global diabetes market is estimated at hundreds of billions of dollars. The pulmonary hypertension market is also significant, in the tens of billions. MannKind is targeting niche segments within these larger markets. The Technosphere platform could be expanded into other therapeutic areas.
Upturn SWOT Analysis
Strengths
- Technosphere platform for rapid drug delivery
- Afrezza's rapid-acting insulin profile
- Partnership with United Therapeutics for Tyvaso DPI
- Specialized focus on inhaled therapeutics
Weaknesses
- Limited financial resources compared to larger pharmaceutical companies
- Afrezza's slower market adoption
- Reliance on partnerships for commercialization of some products
- History of losses
Opportunities
- Expansion of Technosphere platform to other therapeutic areas
- Increased market penetration of Afrezza with improved patient education
- Development of new inhaled therapies
- Potential for strategic partnerships and acquisitions
Threats
- Competition from established pharmaceutical companies
- Regulatory challenges and clinical trial risks
- Patent expirations
- Economic downturns affecting healthcare spending
Competitors and Market Share
Key Competitors
- NVO
- LLY
- SNY
Competitive Landscape
MannKind faces intense competition from established diabetes and pulmonary hypertension drug manufacturers. Its competitive advantage lies in its novel inhaled drug delivery technology, but it needs to overcome challenges related to market adoption and brand awareness.
Growth Trajectory and Initiatives
Historical Growth: MannKind's growth has been uneven due to product launches, partnerships, and regulatory challenges. Revenue growth has varied, dependent on product adoption and market conditions.
Future Projections: Analyst estimates suggest continued growth driven by Afrezza and Tyvaso DPI, but these estimates are subject to change.
Recent Initiatives: Recent strategic initiatives include expanding the Afrezza sales force, partnering with United Therapeutics, and exploring new indications for the Technosphere platform.
Summary
MannKind Corp is a specialty pharmaceutical company focused on inhaled therapies, primarily Afrezza and Tyvaso DPI. The company has a novel drug delivery technology but faces significant competition. Partnerships are crucial for its success. Future growth depends on increasing market penetration and expanding its pipeline.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Filings (SEC)
- Analyst Reports
- Press Releases
- Financial News Outlets
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Investment decisions should be based on individual research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About MannKind Corp
Exchange NASDAQ | Headquaters Danbury, CT, United States | ||
IPO Launch date 2004-07-28 | CEO & Director Dr. Michael E. Castagna Pharm.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 403 | Website https://www.mannkindcorp.com |
Full time employees 403 | Website https://www.mannkindcorp.com | ||
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of therapeutic products and services for endocrine and orphan lung diseases in the United States. It offers Afrezza Inhalation Powder, an inhaled insulin used to improve glycemic control in adults with diabetes; the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults; and Tyvaso DPI for the treatment of pulmonary arterial hypertension and pulmonary hypertension. The company's product pipeline includes MNKD-101, a nebulized formulation of clofazimine, which is in Phase 3 study, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, which is in phase 1 clinical study, for the treatment of idiopathic pulmonary fibrosis (IPF); MNKD-301, which is in preclinical stage, for cystic fibrosis; and Pediatric Afrezza, which is in phase 3 clinical trial for the treatment of diabetes mellitus. It has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India; and co-promotion agreement with Amphastar for marketing of Baqsimi (glucagon) nasal powder. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.